TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01473732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Target trough level of Tacrolimus 3-5 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Description: Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
Study: NCT01095458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone versus Clinic Weight Management Programs
Description: To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone versus Clinic Weight Management Programs
Description: To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
Study: NCT04724070

Intervention type: GENETIC
Intervention: NGS, PDO/PDX establishment
Description: Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
Study: NCT01473732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
Study: NCT03058692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Multimeric-001 Vaccine
Description: The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is saline injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
Study: NCT02820675

Intervention type: OTHER
Group type: OTHER
Intervention: structured case analysis
Description: implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.

Intervention type: OTHER
Group type: OTHER
Intervention: strucured screening every patient, every shift
Description: implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
Study: NCT00574717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
Study: NCT00974753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.5%
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.5%
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline drops
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline drops
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Study: NCT02688244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No irrigation
Description: Suction only, using suction device
Study: NCT03536585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vulvovaginal treatment
Description: * Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
Study: NCT01798966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study: NCT03576326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drawing Incentive
Description: The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
Study: NCT01759797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra venous injection of stem cell
Description: Intra venous injection of mesenchymal stem cell
Study: NCT02582645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open window technique
Description: palatally impacted canine will be exposed and left without traction for a maximum of 9 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed window technique
Description: palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
Study: NCT00497445

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: angioplasty / surgery
Description: Percutaneous vascular intervention or surgery for peripheral arterial disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty / surgery and exercise therapy
Description: Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
Study: NCT02994537

Intervention type: OTHER
Intervention: Different biochemical results or pathogenesis.
Description: Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
Study: NCT03242681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy Assisted Probing procedure
Description: The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
Study: NCT03667755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding
Description: participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
Study: NCT06371105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-week water-based aerobic training
Description: The water-based aerobic program was adopted from the protocol previously used by Costa et al. (2018, 2020). This training program was carried out thrice a week over 2 non-consecutive days 48 hours apart for 10 weeks according to ACSM guidelines
Study: NCT01751984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks
Study: NCT04186234

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
Study: NCT03870295

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic skin response (SSR) measure
Description: Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sympathetic skin response (SSR) measure
Description: Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
Study: NCT06054100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
Study: NCT04145882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: additional osteotomies
Description: varisation osteotomy, supination osteotomy or both
Study: NCT00857922

Intervention type: OTHER
Intervention: tissue and data repository
Description: Tissue and data will be maintained in a repository for study from consenting subjects.
Study: NCT04145882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional osteotomies
Description: varisation osteotomy, supination osteotomy or both

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional osteotomies
Description: varisation osteotomy, supination osteotomy or both

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional osteotomies
Description: varisation osteotomy, supination osteotomy or both
Study: NCT02433886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Ventral Capsulotomy
Study: NCT02575755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus piperaquine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus piperaquine phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Study: NCT01429493

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiotherapy
Description: Conventional radiotherapy will be used (8 Gy/ 1 fraction).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Biological image-guided radiotherapy with conventional dose.
Description: Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Biological image-guided SBRT with dose-escalation.
Description: Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
Study: NCT02495129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736 lower dose
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736 higher dose
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
Study: NCT04050059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine
Description: In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
Study: NCT01103765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post dilatation after stent deployment
Description: Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: stent deployment without post-dilatation
Description: stent deployment without systematic post dilatation
Study: NCT02246595

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CaCP29

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03200119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily health-related lifestyle modification prescription
Description: Daily health-related lifestyle modification prescription
Study: NCT00257699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ciprofloxacin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: 500 mg bid po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: 250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
Study: NCT03242681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy Assisted Probing procedure
Description: The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
Study: NCT04482296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI with Zinc Sulfate
Description: Zinc sulfate (30 mg) once daily for 8 weeks SSRI
Study: NCT03461107

Intervention type: OTHER
Intervention: No intervention
Study: NCT00918099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Avaulta mesh
Description: Insertion of a mesh vs conventional repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior repair
Description: Conventional repair
Study: NCT01708512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT03946748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3918
Description: Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
Study: NCT02722954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
Study: NCT01618799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: 2 x 25 mg tablet once a day
Study: NCT02722954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
Study: NCT04184830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive brain stimulation
Study: NCT02342964

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of hepatic elasticity
Description: Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE.
Study: NCT02619474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteboard
Description: 1. On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~2. The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~3. Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning.
Study: NCT03499184

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P Flor locally delivered
Description: Locally delivered Lactobacillus reuteri 1.2 CFU per gram

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P Flor systemically administered
Description: Systemically administered Lactobacillus reuteri 1.2 CFU per gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxil 500 mg Oral Capsule
Description: Systemically administered Amoxil 500 mg thrice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl 400 mg Tablet
Description: Systemically administered Metronidazole 400 mg twice daily
Study: NCT02720341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARMin
Description: single sessions of about one hour each
Study: NCT03746327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivextro 200 milligrams Oral Tablet
Description: 200 mg milligram per day during 4 weeks
Study: NCT03217955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-SA
Description: Info has been included in arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Info has been included in arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Info has been included in arm description
Study: NCT03871062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two step anesthesia
Description: conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthesia
Description: conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
Study: NCT03309748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis
Description: American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis
Description: American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis + antimicrobial photodynamic therapy
Description: Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
Study: NCT00861445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM927/Lacosamide
Description: SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
Study: NCT03202342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
Study: NCT03309280

Intervention type: OTHER
Intervention: Duration of intubation
Description: Time between intubation in the operating room and exhumation in the Intensive Care Unit.

Intervention type: OTHER
Intervention: Duration of intubation
Description: Time between intubation in the operating room and exhumation in the Intensive Care Unit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evolution of the renal function
Description: Evolution of the renal function in the next two days

Intervention type: DIAGNOSTIC_TEST
Intervention: Evolution of the renal function
Description: Evolution of the renal function in the next two days
Study: NCT03072212

Intervention type: OTHER
Intervention: Observational study
Description: No intervention

Intervention type: OTHER
Intervention: Observational study
Description: No intervention
Study: NCT03537118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopic + Ultrasound Guidance
Description: Fluoroscopic Guidance Alone
Study: NCT01910064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK530G
Study: NCT01556542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
Description: paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nitinol stent implantation
Description: nitinol stent implantation
Study: NCT03314467

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: * classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: * classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: * classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes
Study: NCT02420106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Medicine
Description: Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
Study: NCT00861445

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets two times a day for 10 weeks